Our findings uncover a novel epigenetic-metabolic crosstalk pathway in NSCLC, providing new insights into the molecular mechanisms of SATB2-mediated tumor suppression and potential therapeutic targets for NSCLC. This evidence concerns the gene SATB2 and non-small cell lung carcinoma.